Literature DB >> 25172419

Facile synthesis of SSR180575 and discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, a potent pyridazinoindole ligand for PET imaging of TSPO in cancer.

Yiu-Yin Cheung1, Michael L Nickels2, Dewei Tang2, Jason R Buck2, H Charles Manning3.   

Abstract

A novel synthesis of the translocator protein (TSPO) ligand 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide (SSR180575, 3) was achieved in four steps from commercially available starting materials. Focused structure-activity relationship development about the pyridazinoindole ring at the N3 position led to the discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide (14), a novel ligand of comparable affinity. Radiolabeling with fluorine-18 ((18)F) yielded 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide ([(18)F]-14) in high radiochemical yield and specific activity. In vivo studies of [(18)F]-14 revealed this agent as a promising probe for molecular imaging of glioma.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fluorine-18; Glioma; PET; SSR180575; TSPO

Mesh:

Substances:

Year:  2014        PMID: 25172419      PMCID: PMC4163096          DOI: 10.1016/j.bmcl.2014.07.091

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  33 in total

Review 1.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

Review 2.  Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function.

Authors:  Vassilios Papadopoulos; Mario Baraldi; Tomás R Guilarte; Thomas B Knudsen; Jean-Jacques Lacapère; Peter Lindemann; Michael D Norenberg; David Nutt; Abraham Weizman; Ming-Rong Zhang; Moshe Gavish
Journal:  Trends Pharmacol Sci       Date:  2006-07-05       Impact factor: 14.819

Review 3.  Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas.

Authors:  Frederic G Dhermain; Peter Hau; Heinrich Lanfermann; Andreas H Jacobs; Martin J van den Bent
Journal:  Lancet Neurol       Date:  2010-08-10       Impact factor: 44.182

4.  Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide.

Authors:  Dewei Tang; Matthew R Hight; Eliot T McKinley; Allie Fu; Jason R Buck; R Adam Smith; Mohammed Noor Tantawy; Todd E Peterson; Daniel C Colvin; M Sib Ansari; Michael Nickels; H Charles Manning
Journal:  J Nucl Med       Date:  2012-01-17       Impact factor: 10.057

5.  Binding characteristics of SSR180575, a potent and selective peripheral benzodiazepine ligand.

Authors:  V Vin; N Leducq; F Bono; J M Herbert
Journal:  Biochem Biophys Res Commun       Date:  2003-10-24       Impact factor: 3.575

Review 6.  The peripheral benzodiazepine receptor: a promising therapeutic drug target.

Authors:  Sylvaine Galiegue; Norbert Tinel; Pierre Casellas
Journal:  Curr Med Chem       Date:  2003-08       Impact factor: 4.530

7.  Rapid, Microwave-Assisted Organic Synthesis of Selective (V600E)BRAF Inhibitors for Preclinical Cancer Research.

Authors:  Jason R Buck; Sam Saleh; Md Imam Uddin; H Charles Manning
Journal:  Tetrahedron Lett       Date:  2012-06-06       Impact factor: 2.415

8.  Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.

Authors:  Nathalie L Jansen; Bogdana Suchorska; Vera Wenter; Sabina Eigenbrod; Christine Schmid-Tannwald; Andreas Zwergal; Maximilian Niyazi; Mark Drexler; Peter Bartenstein; Oliver Schnell; Jörg-Christian Tonn; Niklas Thon; Friedrich-Wilhelm Kreth; Christian la Fougère
Journal:  J Nucl Med       Date:  2013-12-30       Impact factor: 10.057

9.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.

Authors:  Benoit Pirotte; Serge Goldman; Nicolas Massager; Philippe David; David Wikler; Arlette Vandesteene; Isabelle Salmon; Jacques Brotchi; Marc Levivier
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

10.  In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106.

Authors:  Akihiro Takano; Fredrik Piehl; Jan Hillert; Andrea Varrone; Sangram Nag; Balázs Gulyás; Per Stenkrona; Victor L Villemagne; Christopher C Rowe; Richard Macdonell; Nabil Al Tawil; Thomas Kucinski; Torsten Zimmermann; Marcus Schultze-Mosgau; Andrea Thiele; Anja Hoffmann; Christer Halldin
Journal:  EJNMMI Res       Date:  2013-04-24       Impact factor: 3.138

View more
  9 in total

1.  New structure-activity relationships of N-acetamide substituted pyrazolopyrimidines as pharmacological ligands of TSPO.

Authors:  Jun Li; Michael L Schulte; Michael L Nickels; H Charles Manning
Journal:  Bioorg Med Chem Lett       Date:  2016-06-16       Impact factor: 2.823

2.  Evaluation of TSPO PET Ligands [18F]VUIIS1009A and [18F]VUIIS1009B: Tracers for Cancer Imaging.

Authors:  Dewei Tang; Jun Li; Jason R Buck; Mohamed Noor Tantawy; Yan Xia; Joel M Harp; Michael L Nickels; Jens Meiler; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2017-08       Impact factor: 3.488

3.  A unified structural model of the mammalian translocator protein (TSPO).

Authors:  Yan Xia; Kaitlyn Ledwitch; Georg Kuenze; Amanda Duran; Jun Li; Charles R Sanders; Charles Manning; Jens Meiler
Journal:  J Biomol NMR       Date:  2019-06-26       Impact factor: 2.835

4.  [18F]FEPPA: Improved Automated Radiosynthesis, Binding Affinity, and Preliminary in Vitro Evaluation in Colorectal Cancer.

Authors:  Neydher Berroterán-Infante; Theresa Balber; Petra Fürlinger; Michael Bergmann; Rupert Lanzenberger; Marcus Hacker; Markus Mitterhauser; Wolfgang Wadsak
Journal:  ACS Med Chem Lett       Date:  2018-02-21       Impact factor: 4.345

5.  TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions.

Authors:  Allison S Cohen; Jun Li; Matthew R Hight; Eliot McKinley; Allie Fu; Adria Payne; Yang Liu; Dawei Zhang; Qing Xie; Mingfeng Bai; Gregory D Ayers; Mohammed Noor Tantawy; Jarrod A Smith; Frank Revetta; M Kay Washington; Chanjuan Shi; Nipun Merchant; H Charles Manning
Journal:  Clin Cancer Res       Date:  2020-09-15       Impact factor: 12.531

6.  Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[18F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide (18F-VUIIS1018A) to Image Glioma.

Authors:  Dewei Tang; Jun Li; Michael L Nickels; Gang Huang; Allison S Cohen; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

7.  Preclinical TSPO Ligand PET to Visualize Human Glioma Xenotransplants: A Preliminary Study.

Authors:  Jason R Buck; Eliot T McKinley; Allie Fu; Ty W Abel; Reid C Thompson; Lola Chambless; Jennifer M Watchmaker; James P Harty; Michael K Cooper; H Charles Manning
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

8.  Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.

Authors:  Renee Sokias; Eryn L Werry; Sook W Chua; Tristan A Reekie; Lenka Munoz; Erick C N Wong; Lars M Ittner; Michael Kassiou
Journal:  Medchemcomm       Date:  2016-11-15       Impact factor: 3.597

Review 9.  A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.

Authors:  Julie Bolcaen; Janke Kleynhans; Shankari Nair; Jeroen Verhoeven; Ingeborg Goethals; Mike Sathekge; Charlot Vandevoorde; Thomas Ebenhan
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.